Norvaline

Identification

Summary

Norvaline is a drug used to treat vaginal inflammation with betamethasone and tyrothricin.

Generic Name
Norvaline
DrugBank Accession Number
DB04185
Background

Norvaline is an isomer of the more common amino acid valine.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 117.1463
Monoisotopic: 117.078978601
Chemical Formula
C5H11NO2
Synonyms
  • (S)-2-Aminopentanoic acid
  • 2-Aminopentanoic acid
  • 2-Aminovaleric acid
  • L-2-aminopentanoic acid
  • L-2-Aminovaleric acid
  • L-Norvaline
External IDs
  • NSC-203786

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatVaginal inflammationCombination Product in combination with: Tyrothricin (DB13503), Betamethasone (DB00443), Norvaline (DB04185)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGlycine amidinotransferase, mitochondrialNot AvailableHumans
UOrnithine carbamoyltransferase, mitochondrialNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DELTAVAGINNorvaline (100 mg) + Betamethasone (2 mg) + Tyrothricin (10 mg)InsertVaginalFarmitalia Industria Chimico Farmaceutica S.R.L.2014-07-08Not applicableItaly flag
DELTAVAGINNorvaline (100 mg) + Betamethasone (2 mg) + Tyrothricin (10 mg)InsertVaginalFarmitalia Industria Chimico Farmaceutica S.R.L.2014-07-082022-02-16Italy flag
DELTAVAGINNorvaline (100 mg) + Betamethasone (2 mg) + Tyrothricin (10 mg)InsertVaginalFarmitalia Industria Chimico Farmaceutica S.R.L.2014-07-082022-02-16Italy flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
L-alpha-amino acids
Alternative Parents
Methyl-branched fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Amine / Amino acid / Branched fatty acid / Carbonyl group / Carboxylic acid / Fatty acid / Fatty acyl / Hydrocarbon derivative / L-alpha-amino acid
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
2-aminopentanoic acid, (R)-fenbuconazole (CHEBI:18314) / Amino fatty acids (C01826) / Amino fatty acids (LMFA01100041)
Affected organisms
Not Available

Chemical Identifiers

UNII
A70UKS48FE
CAS number
6600-40-4
InChI Key
SNDPXSYFESPGGJ-BYPYZUCNSA-N
InChI
InChI=1S/C5H11NO2/c1-2-3-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
IUPAC Name
(2S)-2-aminopentanoic acid
SMILES
CCC[C@H](N)C(O)=O

References

Synthesis Reference

Naoyuki Harada, Masataka Hikota, "Norvaline Derivative and Method for Preparation Thereof." U.S. Patent US20080076769, issued March 27, 2008.

US20080076769
General References
Not Available
KEGG Compound
C01826
PubChem Compound
65098
PubChem Substance
46507762
ChemSpider
58608
BindingDB
50357215
ChEBI
18314
ChEMBL
CHEMBL55612
ZINC
ZINC000000391821
PDBe Ligand
NVA
Wikipedia
Norvaline
PDB Entries
1b6h / 1c9y / 1fb5 / 1jdx / 1obc / 1obh / 1z3m / 1z3p / 1znm / 2bte
show 15 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InsertVaginal
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility212.0 mg/mLALOGPS
logP-2ALOGPS
logP-1.9Chemaxon
logS0.26ALOGPS
pKa (Strongest Acidic)2.71Chemaxon
pKa (Strongest Basic)9.53Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area63.32 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity29.62 m3·mol-1Chemaxon
Polarizability12.51 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-0006-0910000000-beefdf719a6886968b7c
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-014i-0790000000-e7b2312067ea2f580f89
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00fu-9000000000-463db7a51bc96eebb0fc
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0006-0900000000-a6657581da86b5e16b49
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00dl-8900000000-d938851c18aaa72fa65d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-aa4cfcf519f06eec7d88
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-4e82e4f432ac9f12cbcb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-6900000000-4f8a15a515f7662399b9
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-0f41e9f1f44727ed0171
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00xr-8900000000-a018bb35506cefdb80bd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9000000000-d40d2fdb101f11e267b5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9000000000-376f2fb607142668c579
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05fu-9000000000-a8afb39a0414ea34be89
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-a96a85910f51c12a4199
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-9000000000-8e18b75f54c0cafa716a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9000000000-9e879db3e72d74e99b8b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-3900000000-eff8fa108d5a9eda919c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-8448c3d7c96f63358bca
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-96adcec4b9ab0335ee68
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-6900000000-a4298dbac48fad4ac63c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-1159d9192f7282898f53
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-122.6187618
predicted
DarkChem Lite v0.1.0
[M-H]-123.15447
predicted
DeepCCS 1.0 (2019)
[M+H]+123.3455618
predicted
DarkChem Lite v0.1.0
[M+H]+125.97095
predicted
DeepCCS 1.0 (2019)
[M+Na]+122.6319618
predicted
DarkChem Lite v0.1.0
[M+Na]+134.57912
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Glycine amidinotransferase activity
Specific Function
Catalyzes the biosynthesis of guanidinoacetate, the immediate precursor of creatine. Creatine plays a vital role in energy metabolism in muscle tissues. May play a role in embryonic and central ner...
Gene Name
GATM
Uniprot ID
P50440
Uniprot Name
Glycine amidinotransferase, mitochondrial
Molecular Weight
48455.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Phospholipid binding
Specific Function
Not Available
Gene Name
OTC
Uniprot ID
P00480
Uniprot Name
Ornithine carbamoyltransferase, mitochondrial
Molecular Weight
39934.775 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 09, 2021 08:40